Wegovy 7.2mg in the UK: Who May Benefit From the New Higher Dose?

For many people using Wegovy, reaching the standard maintenance dose of 2.4mg can lead to significant weight loss and improvements in overall health. However, weight loss journeys are rarely identical, and some patients may find their progress slows despite following their prescribed treatment plan.

The introduction of Wegovy 7.2mg could provide an additional option for eligible adults living with obesity who require further support with weight management.

If you're already using Wegovy or considering treatment, here's what you need to know about the higher dose and who may benefit from it.

What Is Wegovy 7.2mg?

Wegovy contains semaglutide, a medication that belongs to a class of medicines known as GLP-1 receptor agonists.

It works by mimicking the action of a naturally occurring hormone called GLP-1, which helps regulate appetite, food intake, and feelings of fullness. By reducing hunger and helping patients feel satisfied with smaller portions, Wegovy can support sustainable weight loss when combined with healthy lifestyle changes. Wegovy 7.2mg contains the same active ingredient as existing Wegovy doses. The difference is that it delivers a larger amount of semaglutide each week.

While the standard maintenance dose remains 2.4mg for most patients, a higher dose may offer additional support for some individuals who have not achieved sufficient weight loss on the lower maintenance dose.

What Do Clinical Studies Show?

Research into higher-dose semaglutide has shown promising results.

In the STEP UP Phase 3b clinical trial, adults living with obesity who received semaglutide 7.2mg achieved greater average weight loss than those receiving the standard 2.4mg maintenance dose.

Participants were followed for 72 weeks while also making lifestyle changes such as improving their diet and increasing physical activity.

Key findings included:

1. Average weight loss approaching 19% of starting body weight
2. Nearly half of participants losing at least 20% of their body weight
3. A significant proportion achieving weight reductions of 25% or more

These findings suggest that some patients may achieve additional weight loss with a higher dose of semaglutide.

However, individual results can vary considerably depending on factors such as treatment adherence, lifestyle habits, medical history, and metabolic differences.

Can You Start on Wegovy 7.2mg?

No. Wegovy treatment always begins at a lower dose to allow the body time to adjust and help minimise side effects.

Patients typically follow a gradual dose escalation schedule:

1. 0.25mg once weekly
2. 0.5mg once weekly
3. 1mg once weekly
4. 1.7mg once weekly
5. 2.4mg once weekly maintenance dose

Only after reaching and tolerating the maintenance dose would a healthcare professional consider whether a higher dose may be appropriate.

Any decision to increase treatment should be based on a full clinical assessment and ongoing review of treatment progress.

What Happens If Weight Loss Slows on Wegovy?

Many patients experience periods where weight loss becomes slower or appears to plateau.

This does not necessarily mean the medication has stopped working.

As body weight decreases, the body naturally adapts, and weight loss may become less rapid over time. Lifestyle factors such as food choices, physical activity levels, sleep quality, and stress can also influence progress.

For some patients, clinicians may consider whether treatment adjustments could be beneficial. However, increasing the dose is only one of several factors that may be reviewed.

Regular follow-up appointments can help ensure treatment continues to support long-term weight management goals.

Is a Higher Dose Always Better?

Not necessarily. Although higher-dose semaglutide produced stronger average weight loss results in clinical studies, the highest dose is not automatically the best option for every patient.

Many individuals achieve excellent results on the standard 2.4mg maintenance dose and may not require any further increase.

Others may find that side effects become more noticeable at higher doses. The goal of treatment is often to find the lowest effective dose that provides meaningful and sustainable weight loss while remaining well tolerated.

A personalised treatment approach is generally more effective than simply using the highest available dose.

Side Effects of Wegovy 7.2mg

The safety profile of higher-dose semaglutide appears broadly similar to lower doses.

The most commonly reported side effects affect the digestive system and may include:

1. Nausea
2. Vomiting
3. Diarrhoea
4. Constipation
5. Stomach pain or abdominal discomfort

These side effects are often most noticeable during dose escalation and may improve as treatment continues.

Some participants in clinical studies also reported altered skin sensations such as tingling or increased sensitivity. These cases were generally mild and resolved without discontinuing treatment.

If side effects become difficult to manage, your clinician may recommend remaining at a lower dose or adjusting your treatment plan.

Who May Be Suitable for Wegovy 7.2mg?

A higher dose may be considered for adults living with obesity who have already progressed through standard Wegovy treatment and require additional support to achieve their weight management goals.

Factors that may be considered during assessment include:

1. Current BMI
2. Weight loss achieved so far
3. Existing health conditions
4. Medication history
5. Side effect experience
6. Overall treatment objectives

Because obesity affects every individual differently, suitability for a higher dose should always be determined on a case-by-case basis.

Is Wegovy 7.2mg Available in the UK?

Yes. Wegovy 7.2mg is approved in the UK for eligible adults living with obesity. In April 2026, the Medicines and Healthcare products Regulatory Agency (MHRA) approved a dedicated single-dose 7.2mg Wegovy pen, allowing patients to receive the maximum weekly dose through one injection.

Frequently Asked Questions

1. What is Wegovy 7.2mg?

Wegovy 7.2mg is a higher-dose version of semaglutide used in weight management. It contains the same active ingredient as other Wegovy doses but delivers a greater amount of medication each week.

1. Can I move straight from 2.4mg to 7.2mg?

Any dose increase should only be made under the supervision of a healthcare professional following an assessment of treatment response and tolerability.

1. How much weight can you lose with Wegovy 7.2mg?

Clinical studies have reported average weight loss approaching 19% of starting body weight when combined with diet and lifestyle changes. Individual results can vary.

1. Does Wegovy 7.2mg cause more side effects?

Some patients may experience an increased likelihood of side effects at higher doses, particularly gastrointestinal symptoms such as nausea and diarrhoea.

1. Is Wegovy 7.2mg suitable for everyone?

No. Suitability depends on factors such as BMI, medical history, current medications, treatment response, and overall health. A healthcare professional will determine whether a higher dose may be appropriate.

Important Safety Information

Wegovy is a prescription-only medicine and is not suitable for everyone.

You should not use Wegovy if you:

1. Have a personal or family history of medullary thyroid carcinoma (MTC)
2. Have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2)
3. Have experienced a serious allergic reaction to semaglutide
4. Are pregnant, planning a pregnancy, or breastfeeding

Always discuss your full medical history and current medications with a healthcare professional before starting or changing treatment.

Speak to Farmeci About Your Options

Choosing the right weight loss treatment is about finding an approach that aligns with your health profile, treatment response, and long-term goals.

At Farmeci, our clinicians provide personalised assessments and evidence-based guidance to help patients explore suitable weight management options.

If you'd like to learn more about Wegovy and your eligibility for treatment, book a consultation with the Farmeci team today.